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Abstract
In May 2006, a workshop on Expression array analyses in breast
cancer taxonomy was held at the International Agency for
Research on Cancer (IARC). The workshop covered an array of
topics from the validity of the currently defined breast tumor
subtypes and other expression profile-based signatures to the
technical limitations of expression analysis and the types of
platforms on which these omics results will eventually reach clinical
practice. Overall, the workshop participants believed firmly that
tumor taxonomy is likely to yield improved prognostic and
predictive markers. Even so, further standardization and validation
are required before clinical trials are set in motion.
Introduction
In December 2005, participants at an International Agency
for Research on Cancer (IARC) working group on the
molecular pathology of breast cancer spent a considerable
time discussing the potential role of expression profiling in
tumor classification. Those discussions led to a follow-up
meeting, ‘Expression array analyses in breast cancer
taxonomy’, held at IARC in May 2006; the participant list is
given at the end of this report. Presentations and discussions
covered a wide variety of topics within the general subject
and included presentation of results that have not yet been
published. There were areas of near total agreement and
other areas where views were quite divergent. In this report
we summarize six areas of discussion, highlighting areas of
agreement and also pointing out key questions to be
addressed in future studies.
Detection of breast tumor subtypes
Breast cancer subtypes can clearly be identified by means of
expression array analysis [1-3]. With the nearest centroid
method, subtypes defined in one sample series can be
detected in other independent sample series, and some of the
subtypes can be recapitulated by using immunohistochemical
or DNA copy-number-based classifiers [2,4-6]. Among the five
subtypes originally defined by Sørlie and colleagues [1,2], the
basal and luminal-A subtypes are reasonably robust; however,
neither these two nor other less robust subtype classifiers are
necessarily completely optimized.
Other profile-based signatures
Subtype classification as exemplified by the five-type
classifier does not sample all of the signatures available in a
large-scale expression profiling analysis. For example, wound
healing, proliferation, and tumor grade signatures can be
discerned within the data, and these are somewhat
independent of the subtypes [7-9]. At a deeper level of
analysis, mechanistically defined signatures such as the
estrogen receptor (ER)-positive signature and the wound-
healing signature can be understood as regulatory modules,
often containing biologically informative substructure, whose
expression is controlled by the ER, c-Myc, p53, and other key
regulatory proteins [10-13].
Prognostic implications
Beyond subtype classification, expression profile signatures
clearly have prognostic implications [3,10,14-17]. For
example, several research groups have derived signatures
that are intended to predict survival and, eventually, whether
patients will benefit from adjuvant therapy. Applied to
independent data sets, some of these signatures have
demonstrated significant power to predict clinical outcome,
whereas others have not [17]. At a superficial level, there is a
contradiction between efforts to develop breast cancer
subtype classifiers and efforts to develop breast cancer
prognostic signatures: if breast cancer can indeed be
resolved into several independent subtypes, then there is little
reason to expect that the same prognostic signature should
apply to each subtype [18]. Thus, signatures developed from
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patient series that have a particular subtype distribution may
lose some of their efficacy when applied to patient series that
have a different subtype distribution. In contrast, signatures
based on biological phenomena such as wound healing,
proliferation index, or p53 status may transcend subtype and
even find application to other tumor sites.
Application to genetic and molecular
epidemiology
Patients who have an elevated probability of carrying
germline susceptibility gene mutations are sometimes
detectable [19,20]. In the practise of clinical cancer genetics,
mutation screening of high-risk susceptibility genes such as
BRCA1 and BRCA2 is typically limited to individuals who are
high-probability mutation carriers as defined by their personal
and family cancer histories. Expression profiling reveals that
tumors from BRCA1 carriers have a relatively clear signature
that clusters with the basal subtype, whereas tumors from
BRCA2 carriers have a weaker signature that tends to cluster
with the luminal-A subtype. These results are important for
two reasons: first, likely mutation carriers can be identified
even if they do not have a strong family history, so that
unaffected relatives can eventually benefit from a knowledge
of carrier status irrespective of family history; and second,
there are preliminary indications that tumors from BRCA1
and  BRCA2 mutation carriers respond quite differently to
specific chemotherapies than do tumors from non-BRCA
carriers [21]. Identifying signatures typical of tumors from
BRCA1 or BRCA2 mutation carriers can be viewed as an
application of molecular breast cancer classification to
etiological research. Thus, it may be possible to use this
approach to identify homogenous sets of families whose
excess risk is explained by other susceptibility genes, or
homogenous sets of patients whose tumors have arisen
through specific etiological or mechanistic pathways. Ideally,
molecular classification of breast cancer should become a
standard tool in both genetic epidemiological and molecular
epidemiological research on this disease.
Delivery platforms
Breast tumor subtypes and other biological correlates first
observed in expression profiling experiments will eventually
contribute to the clinical management of breast cancer
patients, but the nature of the clinical assays that will be used
to harvest the information remains unclear [22]. One
possibility is that RNA-based expression profiling of limited
panels of validated genes will become an important clinical
tool. However, because fine details of sample acquisition and
preparation can affect the relative abundance of many
transcripts, clinical assays may eventually rest on more stable
molecules. For instance, in the omics technology arena, either
changes in DNA copy number measured by microarray-based
comparative genomic hybridization or patterns of peptide
expression measured by mass spectrometry may eventually
provide similar information in a more robust assay than
expression profiling [6,23]. In contrast, it may be possible to
abstract much of the information available from an expression
profile into a limited number of carefully chosen
immunohistochemistry (IHC) assays and thereby develop
evolved IHC panels that match the prognostic or predictive
value of an expression profile [5,24]. In addition, translation to
clinical practise of medically useful information first gleaned
through expression profiling and other omics technologies
should be sensitive to the clinical laboratory capabilities in
middle-income and low-income countries; this perspective
adds weight to the need to develop evolved IHC assays.
Technical limitations
Expression profiling analyses carried out over the past few
years are still somewhat confounded by technical challenges,
and these challenges are more severe in attempted
comparisons between studies than within individual studies.
Sample manipulation, analysis of case series selected by
means of different ascertainment criteria, and cross-platform
inconsistency all contribute to discordant study results. For
example, comparative experiments performed on surgical
samples that were exposed to open air in the operating room
for different lengths of time reveal a small but clearly
detectable set of genes whose expression is markedly altered
by exposure to air. These genes are often present in
published lists of differentially expressed genes and even
classifiers, indicating that uncontrolled procedural variables
may continue to contribute biologically irrelevant signals to
expression profiles. Age distribution and other ascertainment
criteria influence the relative prevalence of tumor subtypes in
case series, in turn influencing the rank order of fold
expression differences in the resulting expression array data.
Differences in rank order between studies can lead to
classifiers that have little gene overlap, although classifiers
developed from one case series may retain prognostic or
predictive power when applied to data from another case
series. Cross-platform inconsistency operates at two different
levels. (1) In comparing a set of differentially expressed genes
on different platforms, the rank order of fold expression
differences may be systematically different across platforms
as a result of differences in probe performance. As above,
these differences can lead to classifiers that have little gene
overlap. (2) At the other level, there are differences in gene
assignment between platforms. If different platforms assign
different names to the same gene or assign the same name to
different genes, severe cross-platform data incompatibilities
will arise. Combined, these technical shortcomings affect the
validity of some expression signatures and limit the efficacy of
projecting expression signatures between data sets.
Discussion
We look forward to the time when either expression profiling
itself or markers and profiles first defined by expression
profiling experiments become a standard tool for the
management of breast cancer patients. However, several
fundamental questions need to be answered before this can
take place; the following are four examples of these.Page 3 of 4
(page number not for citation purposes)
1. Are the provisionally recognized subclasses (basal,
luminal-A, etc.) the subclasses or signatures that actually
carry the most useful prognostic and differential treatment
information, or is much of the relevant information hidden
in signatures that have yet to be reproducibly defined and
cross-validated?
2. If the different breast tumor subclasses are really
recognized as distinct diseases, does it make sense to
use a single profile to distinguish between patients who
will or will not benefit from adjuvant therapy, or do distinct
prognostic profiles need to be developed for each
subclass?
3. Is the optimal management of a patient with an ER-
negative/basal tumor different from that of a patient with
an ER-negative/luminal-B tumor?
4. Is the optimal management of a BRCA1 carrier with a
breast tumor that has basal features different from that of
a patient who has wild-type BRCA1 and BRCA2 but an
otherwise superficially similar basal tumor?
Finally, we believe firmly that tumor taxonomy is likely to yield
improved molecular prognostic and predictive markers. How-
ever, proper standardization and external validation of
signatures are required before clinical trials should be
contemplated. As such trials are designed, investigators
should be mindful that the efficacy of competing IHC assays
will evolve as independently informative markers are cherry-
picked from omics discovery studies into more traditional
pathology laboratory test formats. The US Program for
Assessment of Clinical Cancer Tests (PACCT) has useful
guidelines for future studies.
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